دورية أكاديمية
أعرض في EDS

Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians.

التفاصيل البيبلوغرافية
العنوان: Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians.
المؤلفون: Gironés R; Medical Oncology Unit, Hospital Lluís Alcanyís, Xátiva, Valencia, Spain. girones_reg@gva.es, Torregrosa D, Gómez-Codina J, Maestu I, Tenias JM, Rosell R
المصدر: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2012 Mar; Vol. 14 (3), pp. 183-9.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2010- >: Milan : Springer Italia
Original Publication: Barcelona, Spain : Doyma, c2005-
مواضيع طبية MeSH: Aged* , Decision Making* , Patient Preference* , Physician-Patient Relations*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , Lung Neoplasms/*drug therapy, Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/psychology ; Choice Behavior/physiology ; Female ; Humans ; Lung Neoplasms/psychology ; Male ; Palliative Care/psychology ; Palliative Care/statistics & numerical data ; Patient Education as Topic ; Surveys and Questionnaires
مستخلص: Purpose: Lung cancer chemotherapy decisions in patients ≥ 70 years old are complex because of toxicity, comorbidity and the limited data on patient preferences. We examined the relationships between preferences and chemotherapy use in this group of patients.
Methods and Patients: We used a questionnaire describing four hypothetical lung cancer treatment options. Eighty-three elderly (≥ 70 years old) lung cancer patients were informed about their diagnosis and therapeutic choices and then asked to choose one of the four options. Patients had previously been included in a prospective study to explore geriatric evaluation in an oncology unit and all had given written informed consent.
Results: Older patients (n=83) diagnosed with lung cancer (non-small- and small-cell lung cancer) from January 2006 to February 2008 were recruited from a single centre. The mean patient age was 77 years (range: 70-91). Eighty-one patients (97.6%) were men. Non-small-cell lung cancer (NSCLC) was the diagnosis in 63 patients (76%). Most patients selected active treatment (38.6% most survival benefit, 18% less survival benefit) and 31.3% selected no active treatment. Elderly lung cancer patients were significantly more likely to accept aggressive treatments despite high reported toxicities. Although most of the patients were symptomatic at diagnosis, the "symptom relief" option was chosen less frequently than the options that could prolong survival. Factors significantly related to patients' attitude toward chemotherapy were age (p<0.001), frailty (p=0.0039), depression and poor performance status (PS).
Conclusion: Elderly lung cancer patients want to be involved in the decision-making process. Survival was the main treatment objective for more than half of the patients in this study. We have not found other published studies about elderly lung cancer patients' decisions about chemotherapy.
References: Med Oncol. 2011 Sep;28(3):661-6. (PMID: 20354816)
J Clin Oncol. 2011 Oct 1;29(28):3825-31. (PMID: 21900105)
Oncologist. 2010;15(6):584-92. (PMID: 20495217)
Lung Cancer. 1997 Aug;18(1):1-20. (PMID: 9268944)
Gynecol Oncol. 2001 Jun;81(3):447-55. (PMID: 11371137)
J Natl Cancer Inst. 2002 Feb 6;94(3):173-81. (PMID: 11830607)
JAMA. 1998 Jun 3;279(21):1709-14. (PMID: 9624023)
Lung Cancer. 2009 Feb;63(2):264-70. (PMID: 18649969)
Eur J Oncol Nurs. 2004 Sep;8(3):257-61. (PMID: 15304233)
BMJ. 1990 Jun 2;300(6737):1458-60. (PMID: 2379006)
Patient Educ Couns. 2001 Nov;45(2):149-57. (PMID: 11687329)
J Clin Oncol. 1997 Jan;15(1):330-40. (PMID: 8996160)
J Clin Oncol. 2010 Jul 1;28(19):3146-53. (PMID: 20516438)
Intern Med. 2005 Feb;44(2):107-13. (PMID: 15750269)
Lung Cancer. 2007 Jun;56(3):433-43. (PMID: 17346847)
J Clin Oncol. 2003 Sep 1;21(17):3214-9. (PMID: 12874269)
Psychooncology. 2009 May;18(5):483-9. (PMID: 18942662)
Lung Cancer. 2002 Nov;38 Suppl 2:S45-50. (PMID: 12431829)
J Clin Oncol. 2002 Sep 1;20(17):3658-64. (PMID: 12202667)
BMJ. 1998 Sep 19;317(7161):771-5. (PMID: 9740561)
J Clin Oncol. 2007 Nov 20;25(33):5275-80. (PMID: 18024875)
Br J Cancer. 2003 Dec 15;89(12):2219-26. (PMID: 14676798)
Ann Oncol. 2010 Apr;21(4):692-706. (PMID: 19717538)
Support Care Cancer. 1994 Jul;2(4):242-4. (PMID: 7522106)
Lung Cancer. 2006 Aug;53(2):171-6. (PMID: 16757059)
Lung Cancer. 2010 Sep;69(3):307-14. (PMID: 20080315)
Lung Cancer. 2010 Aug;69(2):141-7. (PMID: 20570009)
Crit Rev Oncol Hematol. 2008 Oct;68 Suppl 1:S1-8. (PMID: 18752969)
J Clin Oncol. 2010 May 1;28(13):2191-7. (PMID: 20351329)
J Clin Oncol. 2005 Mar 20;23(9):2012-9. (PMID: 15774792)
Chest. 1998 Aug;114(2):593-604. (PMID: 9726750)
تواريخ الأحداث: Date Created: 20120301 Date Completed: 20120622 Latest Revision: 20211021
رمز التحديث: 20240628
DOI: 10.1007/s12094-012-0782-6
PMID: 22374421
قاعدة البيانات: MEDLINE
الوصف
تدمد:1699-3055
DOI:10.1007/s12094-012-0782-6